Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Zambia: HIV deaths on treatment underestimated

People with HIV in Zambia were at least ten times more likely to die in the first two years after starting antiretroviral treatment than European

Published
14 February 2018
By
Keith Alcorn
Darunavir/ritonavir most durable boosted protease inhibitor in European patients, especially those switching treatment for any reason

Darunavir/ritonavir is the most durable boosted protease inhibitor for antiretroviral (ART)-experienced patients, investigators from the EuroSIDA cohort report in HIV Medicine. Patients switching treatment to

Published
13 February 2018
By
Michael Carter
Communication skills training for healthcare workers improves HIV treatment adherence

People with HIV in Tanzania were more likely to report problems with non-adherence to antiretroviral treatment after their healthcare providers underwent training in patient-centred communication

Published
09 February 2018
By
Keith Alcorn
US regulators approve new HIV combo pill containing bictegravir

The US Food and Drug Administration (FDA) yesterday approved Biktarvy, Gilead Sciences' new single tablet antiretroviral regimen containing the HIV integrase inhibitor bictegravir, which was highly effective

Published
08 February 2018
By
Liz Highleyman
ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment

Today ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the start of a phase III study designed to establish if adults with HIV-1 with current virologic suppression on a tenofovir alafenamide fumarate (TAF)-based regimen of at least three drugs are able to maintain viral suppression upon switching to a two-drug regimen (2DR) of dolutegravir (TIVICAY) and lamivudine (EPIVIR).

Published
08 February 2018
From
ViiV press release
US FDA approves Gilead triple HIV drug, rival files lawsuit

The U.S. Food and Drug Administration on Wednesday approved Biktarvy, Gilead Sciences Inc’s once-daily, triple-combination tablet for treatment of HIV infection, paving the way for the biotech company to capture more of the multibillion-dollar HIV drug market.

Published
08 February 2018
From
Reuters
Case Western Reserve and Sangamo Therapeutics Announce $11 Million NIH Grant for Study of Gene-Edited T Cells for Viral Eradication of HIV

The grant will fund a clinical trial to test the hypothesis that treating patients with their own gene-edited T cells may lead to a sustained increase in T cell counts and eradication of latent HIV reservoirs.

Published
07 February 2018
From
Sangamo press release
Generic drugs for HIV treatment may save money, but barriers to prescription make savings elusive

The potential savings from prescribing generic antiretrovirals predicted by economic models may be overstated and numerous barriers need to be overcome to bring down the

Published
07 February 2018
By
Keith Alcorn
What does an HIV cure mean to you?

We did a study to better understand the meanings of HIV cure among people living with HIV. This is critical to reconcile what would be clinically feasible with what would be meaningful for people living with HIV.

Published
06 February 2018
From
Positively Aware
Disruptions in PrEP adherence provide insights into intimate partner violence

New study finds strong links between PrEP disruptions and intimate partner violence in Kenya and Uganda. Combined interventions could be key to improving adherence and linking victims to support services.

Published
02 February 2018
From
Avert
← First12345...461Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.